CDC logo, Safer Healthier People CDC HomeCDC SearchCDC Health Topics A-Z
NIOSH - National Institute for Occupational Safety and Health

Search NIOSH  |  NIOSH Home  |  NIOSH Topics  |  Site Index  |  Databases and Information Resources  |  NIOSH Products  |  Contact Us




Butyric acid, 4 - (p - bis (2 - chloroethyl) aminophenyl) -

RTECS #: ES7525000

CAS #: 305-03-3

UPDATE: May 2009 MW: 304.24 MF: C14H19Cl2NO2


NOTE:

TABLE OF CONTENTS:
  1. SYNONYMS:
  2. MUTATION DATA:
  3. REPRODUCTIVE EFFECTS DATA:
  4. TUMORIGENIC DATA:
  5. ACUTE TOXICITY DATA:
  6. OTHER MULTIPLE DOSE DATA:
  7. REVIEWS:
  8. NIOSH DOCUMENTATION AND SURVEILLANCE:
  9. STATUS IN FEDERAL AGENCIES:
  10. REFERENCES:

SYNONYMS:

  1. 4 (p - Bis (beta - chloroethyl) aminophenyl) butyric acid
  2. 4 - (Bis (2 - chloroethyl) amino) benzenebutanoic acid
  3. 4 - (p - (Bis (2 - chloroethyl) amino) phenyl) butyric acid
  4. Ambochlorin
  5. Amboclorin
  6. Benzenebutanoic acid, 4 - (bis (2 - chloroethyl) amino) -
  7. Butanoic acid, 4 - (bis (2 - chloroethyl) amino) benzene -
  8. CAB
  9. CB 1348
  10. Chlorambucil
  11. Chloraminophen
  12. Chloraminophene
  13. Chlorobutin
  14. Chlorobutine
  15. Ecloril
  1. Kyselina 4 - (N,N - bis - (2 - chlorethyl) - p - aminofenyl) maselna (Czech)
  2. Leukeran
  3. Linfolizin
  4. Linfolysin
  5. Lympholysin
  6. N,N - Di - 2 - chloroethyl - gamma - p - aminophenylbutyric acid
  7. NCI - C03485
  8. NSC - 3088
  9. Phenylbuttersaeure - lost (German)
  10. Phenylbutyric acid nitrogen mustard
  11. RCRA waste number U035
  12. gamma - (p - Bis (2 - chloroethyl) aminophenyl) butyric acid
  13. gamma - (p - Di (2 - chloroethyl) aminophenyl) butyric acid
  14. p - (N,N - Di - 2 - chloroethyl) aminophenyl butyric acid
  15. p - N,N - Di - (beta - chloroethyl) aminophenyl butyric acid


SKIN AND EYE IRRITATION DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
N/R
 N/R N/R N/R


MUTATION DATA AND REFERENCES:

SYSTEM TEST ROUTE/
ORGANISM/
TISSUE 		DOSE REFERENCE
cytogenetic analysis oral
Drosophila melanogaster 		1 mmol/L/6 hour MUTAEX 19,121,2004
cytogenetic analysis hamster lung 2 µmol/L MUREAV 283,75,1992
cytogenetic analysis unreported route
human 		3 mg/kg/8 week- intermittent HUHEAS 29,100,1979
cytogenetic analysis human lymphocyte 250 µg/L MUREAV 26,205,1974
cytogenetic analysis mouse other cell types 1.5 µmol/L/48 hour MUREAV 617,125,2007
cytogenetic analysis intraperitoneal
rat 		10 mg/kg FCTOD7 22,665,1984
cytogenetic analysis oral
rat 		55 mg/kg FCTOD7 22,665,1984
dominant lethal test intraperitoneal
mouse 		6 mg/kg MUREAV 345,167,1995
DNA adduct Escherichia coli 20 µmol/L MUREAV 89,95,1981
DNA adduct mouse Ascites tumor 20 µmol/L MUREAV 89,95,1981
DNA adduct intraperitoneal
rat 		12 mg/kg EXPEAM 34,1215,1978
DNA damage human lymphocyte 40 µmol/L CNREA8 49,7031,1989
DNA damage human other cell types 400 µmol/L/2 hour JMCMAR 44,694,2001
DNA damage human other cell types 10 µmol/L/1 hour TXCYAC 193,137,2003
DNA damage mammal (species unspecified) lymphocyte 2,500 nmol/L MUREAV 368,235,1996
DNA damage intraperitoneal
mouse 		20 mg/kg MUREAV 467,83,2000
DNA damage other microorganisms 500 µmol/L CNREA8 49,7031,1989
DNA damage Saccharomyes cerevisiae 1 mmol/L MUREAV 58,241,1978
DNA inhibition human HeLa cell 15 µmol/L IJCNAW 16,91,1975
DNA inhibition skin
mouse 		1 pph BJDEAZ 94,1,1976
DNA inhibition intravaginal
mouse 		5,000 ppm JIDEAE 62,378,1974
DNA inhibition mouse embryo 15 mg/L JEEMAF 36,273,1976
DNA inhibition oral
rat 		19 mg/kg MUREAV 68,275,1979
unscheduled DNA synthesis human lymphocyte 1 µmol/L JTEHD6 6,1059,1980
unscheduled DNA synthesis rat other cell types 3,300 nmol/L EJCAAH 11,9,1975
host-mediated assay mouse
Ascites tumor 		365 µg/kg TCMUD8 10,321,1990
mutation in microorganisms Salmonella typhimurium 1 mg/plate (+enzymatic activation step) MUREAV 283,29,1992
mutation in microorganisms Salmonella typhimurium 100 µg/plate (-enzymatic activation step) ENMUDM 8(Suppl 7),1,1986
mutation in microorganisms Saccharomyes cerevisiae 2 mmol/L (-enzymatic activation step) GENTAE 92,83,1979
micronucleus test human lymphocyte 1.5 µmol/L MUREAV 617,125,2007
micronucleus test intraperitoneal
mouse 		4 mg/kg MUREAV 389,3,1997
gene conversion and mitotic recombination oral
Drosophila melanogaster 		0.5 mmol/L/6 hour MUTAEX 19,121,2004
gene conversion and mitotic recombination Saccharomyes cerevisiae 1,000 ppm MUREAV 11,327,1971
mutation in mammalian somatic cells hamster lung 10 µmol/L MUREAV 283,75,1992
mutation in mammalian somatic cells hamster ovary 20 mg/L CNREA8 43,577,1983
morphological transform hamster kidney 80 µg/L BJCAAI 37,873,1978
morphological transform mouse fibroblast 0.1 mg/L/21 day (-enzymatic activation step) EMMUEG 37,231,2001
other mutation test systems human HeLa cell 5 mg/L KSRNAM 20,1974,1986
other mutation test systems intraperitoneal
mouse 		10 mg/kg TOXID9 60,102,2001
other mutation test systems intraperitoneal
rat 		12 mg/kg EXPEAM 34,1215,1978
other mutation test systems intraperitoneal
rat 		10 mg/kg FCTOD7 22,665,1984
other mutation test systems oral
rat 		55 mg/kg FCTOD7 22,665,1984
phage inhibition capacity Escherichia coli 200 mg/L ARMKA7 51,9,1965
phage inhibition capacity other microorganisms 5 mmol/L MUREAV 1,355,1964
sister chromatid exchange hamster lung 200 nmol/L MUREAV 283,75,1992
sister chromatid exchange hamster ovary 75 µg/L MUREAV 175,165,1986
sister chromatid exchange unreported route
human 		8,800 µg/kg/44 day EJCODS 18,979,1982
sister chromatid exchange human lymphocyte 200 nmol/L MUREAV 190,205,1987
sister chromatid exchange human lymphocyte 225 µg/L EMMUEG 14,6,1989
sex chromosome loss and nondisjunction unreported route
Drosophila melanogaster 		10 mmol/L ANYAA9 160,228,1969
sex chromosome loss and nondisjunction oral
Drosophila melanogaster 		2,000 ppm ENMUDM 7,677,1985
sex chromosome loss and nondisjunction oral
Drosophila melanogaster 		0.5 mmol/L/6 hour MUTAEX 19,121,2004
specific locus test oral
Drosophila melanogaster 		300 µmol/L MUREAV 242,169,1990
specific locus test oral
human 		3.65 mg/kg/16 week MUTAEX 16,197,2001
specific locus test human lymphocyte 0.5 µmol/L/1 hour MUTAEX 16,197,2001
specific locus test intraperitoneal
mouse 		10 mg/kg MUREAV 358,25,1996
specific locus test oral
other insects 		5 mmol/L/24 hour MUREAV 478,107,2001
heritable translocation test oral
Drosophila melanogaster 		3,000 ppm ENMUDM 7,677,1985
heritable translocation test intraperitoneal
mouse 		6 mg/kg MUREAV 345,167,1995


REPRODUCTIVE EFFECTS DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
hamster 		lowest published toxic dose: 13,500 µg/kg (8 day pregnant) Reproductive: Other developmental abnormalities TJADAB 29(2),30A,1984
intraperitoneal
mouse 		lowest published toxic dose: 4 mg/kg (1 day male) Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) CNREA8 42,122,1982
intraperitoneal
mouse 		lowest published toxic dose: 7 mg/kg (11 day pregnant) Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)

Reproductive: Specific developmental abnormalities: Musculoskeletal system 		TJADAB 28,29,1983
intraperitoneal
rat 		lowest published toxic dose: 12 mg/kg (13 day pregnant) Reproductive: Effects on embryo or fetus: Fetal death CTRRDO 60,477,1976
intraperitoneal
rat 		lowest published toxic dose: 6 mg/kg (13 day pregnant) Reproductive: Specific developmental abnormalities: Central nervous system

Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) 		PSEBAA 139,62,1972
intraperitoneal
rat 		lowest published toxic dose: 4 mg/kg (13 day pregnant) Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)

Reproductive: Specific developmental abnormalities: Musculoskeletal system 		CTRRDO 60,477,1976
intraperitoneal
rat 		lowest published toxic dose: 6 mg/kg (10 day pregnant) Reproductive: Specific developmental abnormalities: Urogenital system ANREAK 139,145,1961
intraperitoneal
rat 		lowest published toxic dose: 6 mg/kg (12 day pregnant) Reproductive: Effects on embryo or fetus: Extra embryonic structures (e.g., placenta, umbilical cord)

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) 		EXPEAM 27,1329,1971
intraperitoneal
rat 		lowest published toxic dose: 3 mg/kg (3 day pregnant) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on embryo or fetus: Cytological changes (including somatic cell genetic material) 		TCMUD8 4,341,1984
oral
mouse 		lowest published toxic dose: 14,200 µg/kg (11 day pregnant) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Specific developmental abnormalities: Central nervous system

Reproductive: Specific developmental abnormalities: Musculoskeletal system 		TJADAB 12,71,1975
oral
mouse 		lowest published toxic dose: 3 mg/kg (7 day pregnant) Reproductive: Effects on embryo or fetus: Cytological changes (including somatic cell genetic material)

Reproductive: Specific developmental abnormalities: Central nervous system 		TJADAB 30(1),8A,1984
oral
mouse 		lowest published toxic dose: 80 mg/kg (8-12 day pregnant) Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth) TCMUD8 6,361,1986
oral
mouse 		lowest published toxic dose: 4 mg/kg (9 day pregnant) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Central nervous system

Reproductive: Specific developmental abnormalities: Musculoskeletal system 		TJADAB 34,449,1986
oral
rat 		lowest published toxic dose: 8 mg/kg (15 day pregnant) Reproductive: Specific developmental abnormalities: Central nervous system

Reproductive: Specific developmental abnormalities: Eye, ear 		40YJAX -,107,1979
oral
rat 		lowest published toxic dose: 6 mg/kg (11 day pregnant) Reproductive: Specific developmental abnormalities: Musculoskeletal system 40YJAX -,107,1979
oral
rat 		lowest published toxic dose: 8 mg/kg (11 day pregnant) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) 40YJAX -,107,1979
oral
rat 		lowest published toxic dose: 10 mg/kg (15 day pregnant) Reproductive: Effects on embryo or fetus: Fetal death 40YJAX -,107,1979
oral
woman 		lowest published toxic dose: 13 mg/kg (56 day prior to copulation) Reproductive: Maternal effects: Menstrual cycle changes or disorders JAMAAP 191,444,1965
oral
woman 		lowest published toxic dose: 5,160 µg/kg (33-75 day pregnant) Reproductive: Specific developmental abnormalities: Urogenital system JAMAAP 186,74,1963
parenteral
rat 		lowest published toxic dose: 8 mg/kg (13 day pregnant) Reproductive: Effects on embryo or fetus: Cytological changes (including somatic cell genetic material) JEEMAF 18,215,1967
subcutaneous
mouse 		lowest published toxic dose: 5 mg/kg (10 day pregnant) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system

Reproductive: Specific developmental abnormalities: Urogenital system 		RFGOAO 70,419,1975
unreported route
man 		lowest published toxic dose: 143 µg/kg (6 day male) Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) CANCAR 25,1026,1970
unreported route
man 		lowest published toxic dose: 1 mg/kg (55 week male) Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) JAMAAP 217,1662,1971
unreported route
man 		lowest published toxic dose: 5,857 µg/kg (30 week male) Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) JRPFA4 33,155,1973


TUMORIGENIC DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
mouse 		lowest published toxic dose: 18 mg/kg/4 week Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Tumors 		JNCIAM 36,915,1966
intraperitoneal
rat 		lowest published toxic dose: 120 mg/kg/26 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia

Blood: Lymphoma including Hodgkin's disease 		RRCRBU 52,1,1975
intraperitoneal
rat 		toxic dose : 170 mg/kg/26 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia

Blood: Lymphoma including Hodgkin's disease 		RRCRBU 52,1,1975
oral
child 		toxic dose : 108 mg/kg/77 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		AFPEAM 36,592,1979
oral
human 		toxic dose : 141 mg/kg/5 year- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		NEJMAG 304,441,1981
oral
human 		toxic dose : 84 mg/kg/3 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		ACCBAT 38,228,1983
oral
man 		lowest published toxic dose: 84 mg/kg/2.5 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		AMSVAZ 199,373,1976
oral
man 		toxic dose : 59 mg/kg/96 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		NPMDAD 10,1717,1981
oral
woman 		lowest published toxic dose: 101 mg/kg/82 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		GYNOA3 6,115,1978
oral
woman 		toxic dose : 200 mg/kg/6 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		ACHAAH 63,283,1980
oral
woman 		toxic dose : 307 mg/kg/7 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		AIMDAP 134,728,1974
oral
woman 		toxic dose : 180 mg/kg/3 year- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		AIMDAP 137,355,1977
oral
woman 		toxic dose : 135 mg/kg/4 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		AIMDAP 137,355,1977
oral
woman 		toxic dose : 70 mg/kg/94 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		ACCBAT 38,228,1983
skin
mouse 		lowest published toxic dose: 108 mg/kg/9 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Skin and Appendages: Tumors 		BJCAAI 10,363,1956
unreported route
woman 		lowest published toxic dose: 161 mg/kg/3 year- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia 		SJHAAQ 13,179,1974


ACUTE TOXICITY DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intracerebral
rat 		lethal dose (50 percent kill): >400 µg/kg N/R JPPMAB 18,760,1966
intraperitoneal
mouse 		lethal dose (50 percent kill): 20 mg/kg N/R BAXXDU #2028335
intraperitoneal
rat 		lethal dose (50 percent kill): 14 mg/kg N/R ENTOX* -,536,2005
intravenous
dog 		lowest published lethal dose: 3 mg/kg Gastrointestinal: Other changes

Blood: Other changes 		CCSUBJ 2,201,1965
intravenous
monkey 		lowest published lethal dose: 3 mg/kg Gastrointestinal: Other changes

Blood: Other changes 		CCSUBJ 2,201,1965
oral
man 		lowest published toxic dose: 3,571 µg/kg Behavioral: Convulsions or effect on seizure threshold JTCTDW 20,361,1983
oral
mouse 		lethal dose (50 percent kill): 80 mg/kg N/R BAXXDU #2028335
oral
rat 		lethal dose (50 percent kill): 76 mg/kg N/R FCTOD7 22,665,1984
oral
woman 		lowest published toxic dose: 82,600 µg/kg Lung, Thorax, or Respiration: Fibrosis (interstitial)

Lung, Thorax, or Respiration: Cough

Lung, Thorax, or Respiration: Dyspnea 		CANCAR 41,455,1978
subcutaneous
mouse 		lethal dose (50 percent kill): 26 mg/kg N/R BAXXDU #2028335
subcutaneous
rat 		lowest published lethal dose: 32 mg/kg Tumorigenic: Active as anti-cancer agent EJCAAH 13,873,1977


OTHER MULTIPLE DOSE DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
oral
human 		lowest published toxic dose: 16.6 mg/kg/12 week- intermittent Blood: Luekopenia

Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) 		JOPDAB 97,653,1980
oral
rat 		lowest published toxic dose: 21 mg/kg/7 day- intermittent Endocrine: Changes in spleen weight

Immunological Including Allergic: Decrease in humoral immune response

Nutritional and Gross Metabolic: Weight loss or decreased weight gain 		TXCYAC 107,47,1996
oral
rat 		lowest published toxic dose: 140 mg/kg/28 day- intermittent Endocrine: Changes in thymus weight

Related to Chronic Data: Changes in testicular weight 		ATSUDG 8,504,1985


REVIEWS:

ORGANIZATION STANDARD
REFERENCE
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMEMDT 9,125,1975
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMSUDL 7,144,1987
International Agency for Research on Cancer (IARC) Cancer Review Human Sufficient Evidence IMEMDT 26,115,1981
International Agency for Research on Cancer (IARC) Cancer Review Human Inadequate Evidence IMEMDT 9,125,1975
International Agency for Research on Cancer (IARC) Cancer Review Group 1 IMSUDL 7,144,1987
TOXICOLOGY REVIEW
JAMAAP 172,1765,1960
TOXICOLOGY REVIEW
MIMDAL 57,19,1974
TOXICOLOGY REVIEW
32XPAD -,49,1975
TOXICOLOGY REVIEW
ANPIAM 5,447,1965
TOXICOLOGY REVIEW
ADVPA3 4,263,1966
TOXICOLOGY REVIEW
DIMON* 40,258,1994
TOXICOLOGY REVIEW
DIMON* 39,678,1993
TOXICOLOGY REVIEW
FCTOD7 44,1699,2006
TOXICOLOGY REVIEW
ENTOX* -,536,2005
TOXICOLOGY REVIEW
ENTOX* -,384,2005
TOXICOLOGY REVIEW
MUREAV 627,10,2007
TOXICOLOGY REVIEW
MUREAV 584,1,2005
TOXICOLOGY REVIEW
CLLID* 11,641,2007
TOXICOLOGY REVIEW
HUTOX* -,439,1996


STANDARDS AND REGULATIONS:

ORGANIZATION STANDARD
REFERENCE
N/R N/R N/R


NIOSH DOCUMENTATION AND SURVEILLANCE:

ORGANIZATION STANDARD or SURVEY
REFERENCE
National Occupational Exposure Survey 1983 National Occupational Exposure Survey 1983: Hazard Code: X3995;
Number of Industries 1;
Total Number of Facilities 105;
Number of Occupations 4;
Total Number of Employees Exposed 3,719;
Total Number of Female Employees Exposed 2,018


STATUS IN FEDERAL AGENCIES:

ORGANIZATION
REFERENCE
EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat; Sperm morphology-human
EPA GENETOX PROGRAM 1988, Positive: D melanogaster Sex-linked lethal
EPA GENETOX PROGRAM 1988, Positive: S cerevisiae gene conversion; S cerevisiae-reversion
EPA GENETOX PROGRAM 1988, Positive/dose response: In vitro SCE-human lymphocytes
EPA GENETOX PROGRAM 1988, Positive/dose response: In vitro SCE-human
EPA GENETOX PROGRAM 1988, Positive: CHO gene mutation
Used as an antineoplastic agent in the treatment of malignant diseases
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NCI Carcinogenesis Studies (ipr);clear evidence:mouse,rat RRCRBU 52,1,1975
NTP 11th Report on Carcinogens,2004:Known to be human carcinogen


REFERENCES:

CODEN
REFERENCE
32XPAD "Teratology," Berry, C.L., and D.E. Poswillo, eds., New York, Springer, 1975
40YJAX "Evaluation of Embryotoxicity, Mutagenicity and Carcinogenicity Risks In New Drugs, Proceedings of the Symposium on Toxicological Testing for Safety of New Drugs, 3rd, Prague, 1976," Benesova, O., et al., eds., Prague, Czechoslovakia, Univerzita Karlova, 1979
ACCBAT Acta Clinica Belgica. (Ave. E. Mounier, 52 1200 Brussels, Belgium) V.1- 1946-
ACHAAH Acta Haematologica. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.1- 1948-
ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ.
AFPEAM Archives Francaises de Pediatrie. (Doin Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1942-
AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908-
AMSVAZ Acta Medica Scandinavica. (Almqvist & Wiksell, POB 45150, S-10430 Stockholm, Sweden) V.52-224, 1919-88.
ANPIAM Arquivos de Neuro-Psiquiatria. (Caixa Postal 30.657, 01051 Sao Paulo, Brazil) V.1- 1943-
ANREAK Anatomical Record. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1906/08-
ANYAA9 Annals of the New York Academy of Sciences. (New York Academy of Sciences, 2 E. 63rd St., New York, NY 10021) V.1- 1877-
ARMKA7 Archiv fuer Mikrobiologie. (Berlin, Fed. Rep. Ger.) V.1-94, 1930-73. For publisher information, see AMICCW.
ATSUDG Archives of Toxicology, Supplement. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) No.1- 1978-
BAXXDU British UK Patent Application. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231)
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947-
BJDEAZ British Journal of Dermatology. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.63- 1951-
CANCAR Cancer (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1948-
CCSUBJ Cancer Chemotherapy Reports, Part 2. (Washington, DC) V.1-5, 1964-75. For publisher information, see CTRRDO.
CLLID*
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941-
CTRRDO Cancer Treatment Reports. (Washington, DC) V.60-71, 1976-87. For publisher information, see JNCIEQ.
DIMON* Disease-a Month (Chicago : Year Book Publishers) V. 24- 1978-
EJCAAH European Journal of Cancer (Elsevier Science, P.O.Box 7247-7682,Philadelphia,PA 19170 -7682,USA OR Elsevier Science B.V.,P.O.Box 1270,1000 BG Amsterdam,The Netherlands) V. 1- 1965-
EJCODS European Journal of Cancer and Clinical Oncology. (Pergamon Press, c/o Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.17(7)- 25, 1981-89. For publisher information, see EJCAEL
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987-
ENMUDM Environmental Mutagenesis. (New York, NY) V.1-9, 1979-87. For publisher information, see EMMUEG.
ENTOX* Encyclopedia of Toxicology: Reference Book, Elsevier, 2005
EXPEAM Experientia. (Birkhaeuser Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1945-
FCTOD7 Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.20- 1982-
GENTAE Genetics. (Genetics Business Office, POB 64025, Baltimore, MD 21264) V.1- 1916-
GYNOA3 Gynecologic Oncology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1972-
HUHEAS Human Heredity. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.19- 1969-
HUTOX*
IJCNAW International Journal of Cancer. (International Union Against Cancer, 3 rue du Conseil- General, 1205 Geneva, Switzerland) V.1- 1966-
IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972-
IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979-
JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1883-
JEEMAF Journal of Embryology and Experimental Morphology. (Essex, UK) V.1-98, 1953-86. For Publisher information, see DEVPED
JIDEAE Journal of Investigative Dermatology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1938-
JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963-
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8.
JOPDAB Journal of Pediatrics. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141) V.1- 1932-
JPPMAB Journal of Pharmacy and Pharmacology. (Pharmaceutical Soc. of Great Britain, 1 Lambeth High St., London SEI 7JN, UK) V.1- 1949-
JRPFA4 Journal of Reproduction and Fertility. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1960-
JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982-
JTEHD6 Journal of Toxicology and Environmental Health. (Hemisphere Pub., 1025 Vermont Ave., NW, Washington, DC 20005) V.1- 1975/76-
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960-
MIMDAL Minnesota Medicine. (Minnesota Medical Assoc., 2221 University Ave., SE, Suite 400, Minneapolis, MN 55414) V.1- 1918-
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-
MUTAEX Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1986-
NEJMAG New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA 02115) V.198- 1928-
NPMDAD Nouvelle Presse Medicale. (Paris, France) V.1-11, 1972-82.
PSEBAA Proceedings of the Society for Experimental Biology and Medicine. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1903/04-
RFGOAO Revue Francaise de Gynecologie et d'Obstetrique. (Masson Pub. USA, Inc., Year Book Medical Pub., 35 E. Wacker Dr., Chicago, IL 60601) V.20- 1920-
RRCRBU Recent Results in Cancer Research. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1965-
SJHAAQ Scandinavian Journal of Haematology. (Munksgaard International Pub., POB 2148, DK-1016 Copenhagen K, Denmark) V.1- 1964-
TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980-
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968-
TOXID9 Toxicologist. (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-
TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973-

Used as an antineoplastic agent in the treatment of malignant diseases

FDA-proprietary drug

RTECS Compound Description:
   Tumorigen
   Drug
   Mutagen
   Reproductive Effector
   Human Data

 Click Here for Additional Information about RTECS

NIOSH Home |  NIOSH Search  |  Site Index  |  Topic List |  RTECS List |  Contact Us